Advances in nanoparticles-based approaches in cancer theranostics

In recent years, the incidence and mortality rate of cancer is raising worldwide. Traditional approaches for cancer patient management including surgery, chemotherapy, radiotherapy, and targeted therapies provide unsatisfactory results and are often associated with adverse reactions. Over the last f...

詳細記述

書誌詳細
出版年:OpenNano
主要な著者: Muhammad Akmal Raheem, Muhammad Ajwad Rahim, Ijaz Gul, Xiaoyun Zhong, Chufan Xiao, Haihui Zhang, Jiazhang Wei, Qian He, Muhammad Hassan, Can Yang Zhang, Dongmei Yu, Vijay Pandey, Ke Du, Runming Wang, Sanyang Han, Yuxing Han, Peiwu Qin
フォーマット: 論文
言語:英語
出版事項: Elsevier 2023-07-01
主題:
オンライン・アクセス:http://www.sciencedirect.com/science/article/pii/S2352952023000312
_version_ 1851842221632913408
author Muhammad Akmal Raheem
Muhammad Ajwad Rahim
Ijaz Gul
Xiaoyun Zhong
Chufan Xiao
Haihui Zhang
Jiazhang Wei
Qian He
Muhammad Hassan
Can Yang Zhang
Dongmei Yu
Vijay Pandey
Ke Du
Runming Wang
Sanyang Han
Yuxing Han
Peiwu Qin
author_facet Muhammad Akmal Raheem
Muhammad Ajwad Rahim
Ijaz Gul
Xiaoyun Zhong
Chufan Xiao
Haihui Zhang
Jiazhang Wei
Qian He
Muhammad Hassan
Can Yang Zhang
Dongmei Yu
Vijay Pandey
Ke Du
Runming Wang
Sanyang Han
Yuxing Han
Peiwu Qin
author_sort Muhammad Akmal Raheem
collection DOAJ
container_title OpenNano
description In recent years, the incidence and mortality rate of cancer is raising worldwide. Traditional approaches for cancer patient management including surgery, chemotherapy, radiotherapy, and targeted therapies provide unsatisfactory results and are often associated with adverse reactions. Over the last few decades, nanotechnology has been a rapidly emerging area of theragnostic in clinical research. It plays a vital role as a bridge between the science and technology of miscellaneous nanoparticles (NPs) and nanomedicine. In general, NPs with a range of sizes of 1–100 nm are thought to be acceptable for cancer medications. NPs may enhance the consistency and solubility of therapeutic drugs to obtain site-specific targeting, controlled release, and safe for healthy organs. NPs have the benefit of pathophysiological properties, enhanced permeability and retention (EPR) effects, and an advantage in cancer targeting. Furthermore, theranostic nanoparticles have been established having incorporated diagnostics and therapy in a single system that might provide more personalized treatment with optimal doses and monitoring the distribution, targeting, and response to therapy by using imaging tools. In this review, we have discussed the classes of nanoparticles, targeting approaches, and implications of NPs for cancer theranostics with recent examples.
format Article
id doaj-art-e3da40a4e9d24b88846d2e992355f9ca
institution Directory of Open Access Journals
issn 2352-9520
language English
publishDate 2023-07-01
publisher Elsevier
record_format Article
spelling doaj-art-e3da40a4e9d24b88846d2e992355f9ca2025-08-19T22:27:54ZengElsevierOpenNano2352-95202023-07-011210015210.1016/j.onano.2023.100152Advances in nanoparticles-based approaches in cancer theranosticsMuhammad Akmal Raheem0Muhammad Ajwad Rahim1Ijaz Gul2Xiaoyun Zhong3Chufan Xiao4Haihui Zhang5Jiazhang Wei6Qian He7Muhammad Hassan8Can Yang Zhang9Dongmei Yu10Vijay Pandey11Ke Du12Runming Wang13Sanyang Han14Yuxing Han15Peiwu Qin16Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaDepartment of Zoology, Ghazi University, D. G Khan 32200, PakistanInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaShenzhen Children's Hospital, Guangdong, PR ChinaInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaSchool of Mechanical, Electrical & Information Engineering, Shandong University, PR ChinaInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaDepartment of Chemical and Environmental Engineering, University of California, Riverside, CA, USAInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR ChinaInstitute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China; Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen, Guangdong Province 518055, PR China; Corresponding author at: Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, PR China.In recent years, the incidence and mortality rate of cancer is raising worldwide. Traditional approaches for cancer patient management including surgery, chemotherapy, radiotherapy, and targeted therapies provide unsatisfactory results and are often associated with adverse reactions. Over the last few decades, nanotechnology has been a rapidly emerging area of theragnostic in clinical research. It plays a vital role as a bridge between the science and technology of miscellaneous nanoparticles (NPs) and nanomedicine. In general, NPs with a range of sizes of 1–100 nm are thought to be acceptable for cancer medications. NPs may enhance the consistency and solubility of therapeutic drugs to obtain site-specific targeting, controlled release, and safe for healthy organs. NPs have the benefit of pathophysiological properties, enhanced permeability and retention (EPR) effects, and an advantage in cancer targeting. Furthermore, theranostic nanoparticles have been established having incorporated diagnostics and therapy in a single system that might provide more personalized treatment with optimal doses and monitoring the distribution, targeting, and response to therapy by using imaging tools. In this review, we have discussed the classes of nanoparticles, targeting approaches, and implications of NPs for cancer theranostics with recent examples.http://www.sciencedirect.com/science/article/pii/S2352952023000312CancerNanotechnologyNanomedicineNanoparticlesTheranostics
spellingShingle Muhammad Akmal Raheem
Muhammad Ajwad Rahim
Ijaz Gul
Xiaoyun Zhong
Chufan Xiao
Haihui Zhang
Jiazhang Wei
Qian He
Muhammad Hassan
Can Yang Zhang
Dongmei Yu
Vijay Pandey
Ke Du
Runming Wang
Sanyang Han
Yuxing Han
Peiwu Qin
Advances in nanoparticles-based approaches in cancer theranostics
Cancer
Nanotechnology
Nanomedicine
Nanoparticles
Theranostics
title Advances in nanoparticles-based approaches in cancer theranostics
title_full Advances in nanoparticles-based approaches in cancer theranostics
title_fullStr Advances in nanoparticles-based approaches in cancer theranostics
title_full_unstemmed Advances in nanoparticles-based approaches in cancer theranostics
title_short Advances in nanoparticles-based approaches in cancer theranostics
title_sort advances in nanoparticles based approaches in cancer theranostics
topic Cancer
Nanotechnology
Nanomedicine
Nanoparticles
Theranostics
url http://www.sciencedirect.com/science/article/pii/S2352952023000312
work_keys_str_mv AT muhammadakmalraheem advancesinnanoparticlesbasedapproachesincancertheranostics
AT muhammadajwadrahim advancesinnanoparticlesbasedapproachesincancertheranostics
AT ijazgul advancesinnanoparticlesbasedapproachesincancertheranostics
AT xiaoyunzhong advancesinnanoparticlesbasedapproachesincancertheranostics
AT chufanxiao advancesinnanoparticlesbasedapproachesincancertheranostics
AT haihuizhang advancesinnanoparticlesbasedapproachesincancertheranostics
AT jiazhangwei advancesinnanoparticlesbasedapproachesincancertheranostics
AT qianhe advancesinnanoparticlesbasedapproachesincancertheranostics
AT muhammadhassan advancesinnanoparticlesbasedapproachesincancertheranostics
AT canyangzhang advancesinnanoparticlesbasedapproachesincancertheranostics
AT dongmeiyu advancesinnanoparticlesbasedapproachesincancertheranostics
AT vijaypandey advancesinnanoparticlesbasedapproachesincancertheranostics
AT kedu advancesinnanoparticlesbasedapproachesincancertheranostics
AT runmingwang advancesinnanoparticlesbasedapproachesincancertheranostics
AT sanyanghan advancesinnanoparticlesbasedapproachesincancertheranostics
AT yuxinghan advancesinnanoparticlesbasedapproachesincancertheranostics
AT peiwuqin advancesinnanoparticlesbasedapproachesincancertheranostics